

# THE LANCET Oncology

## Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Gatta G, Capocaccia R, Botta L, et al, for the RARECAREnet working group. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. *Lancet Oncol* 2017; published online July 4. [http://dx.doi.org/10.1016/S1470-2045\(17\)30445-X](http://dx.doi.org/10.1016/S1470-2045(17)30445-X).

## RARECARENet Working Group

Monika Hackl (Austrian National Cancer Registry); Kris Henau, Nancy Van Damme (Belgian Cancer Registry); Zdravka Valerianova (Bulgaria Cancer Registry); Mario Sekerija (Croatian Cancer Registry); Ladislav Dušek (Czech National Cancer Registry); Margit Mägi (Estonian Cancer Registry); Keiu Paapsi (National Institute for Health Development, Estonia); Nea Malila (Finnish Cancer Registry); Michel Velten (Bas Rhin Cancer Registry); Xavier Troussard (Basse Normandie Haematological malignancies Registry); Veronique Bouvier (Calvados Digestive Tract Registry); Anne-Valérie Guizard (Calvados, Registre Général des Tumeurs); Anne-Marie Bouvier (Côte d'Or Digestive Tract Registry, Burgundy); Patrick Arveux (Côte d'Or Gynaecologic Cancer registry); Marc Maynadié (Côte d'Or Haematological Malignancies Cancer Registry); Anne-Sophie Woronoff (Doubs Cancer Registry); Michel Robaszekiewicz (Finistère Digestive Tract Registry); Isabelle Baldi (Gironde CNS Tumour Registry); Alain Monnereau (Gironde Haematological Malignancies); Brigitte Tretarre (Hérault Cancer Registry); Marc Colonna (Isère Cancer Registry); Florence Molinié (Loire-Atlantique/Vendée Cancer Registry); Simona Bara (Manche Cancer Registry); Claire Schvartz (Marne & Ardennes, Thyroid); Bénédicte Lapôte-Ledoux (Somme Cancer Registry); Pascale Grosclaude (Tarn Cancer Registry); Roland Stabenow (Berlin; Brandenburg; Mecklenburg-West Pomerania; Saxony; Saxony-Anhalt; Thüringen Cancer Registry); Sabine Luttmann (Bremen Cancer Registry, Leibniz Institute for Prevention Research and Epidemiology); Alice Nennecke (Hamburg Cancer Registry); Jutta Engel, Gabriele SchubertFritschle (Munich Cancer Registry); Jan Heidrich (North Rhine-Westphalia Cancer Registry); Bernd Holleczeck (Saarland Cancer Registry); Jón Gunnlaugur Jónasson (Icelandic Cancer Registry); Kerri Clough-Gorr (National Cancer Registry Ireland); Guido Mazzoleni (Alto Adige Cancer Registry); Adriano Giacomini (Biella Cancer Registry); Antonella Suter Sardo (Catanzaro Cancer Registry); Alessandro Barchielli (Firenze-Prato Cancer Registry); Diego Serraino, , Paolo Collarile (Friuli Venezia Giulia, CRO Aviano National Cancer Institute); Fabio Pannozzo (Latina Cancer Registry); Paolo Ricci (Mantova Cancer Registry); Mariangela Autelitano (Milano Cancer Registry); Gianbattista Spagnoli (Modena Cancer Registry); Mario Fusco (Napoli 3 South Cancer Registry); Mario Usala (Nuoro Cancer Registry); Francesco Vitale (Palermo Cancer Registry); Maria Michiara (Parma Cancer Registry); Rosario Tumino (Ragusa Cancer Registry); Lucia Mangone (Reggio Emilia Cancer Registry); Fabio Falcini (Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Forlì, Italy-Azienda Usl della Romagna, Forlì, Italy); Stefano Ferretti (Ferrara Cancer Registry); Rosa Angela Filiberti, Enza Marani (RTR Liguria, IRCCS AOU SM-IST); Anna Luisa Caiazzo, Arturo Iannelli (Salerno Cancer Registry); Flavio Sensi (Sassari Cancer Registry); Silvano Piffer, Maria Gentilini (Servizio Epidemiologia Clinica e Valutativa, Trento); Anselmo Madeddu, Antonino Ziino Colanino (Siracusa Cancer Registry); Sergio Maspero (Sondrio Cancer Registry); Pina Candela (Trapani Cancer Registry); Fabrizio Stracci (Umbria Cancer Registry); Giovanna Tagliabue (Varese Province Cancer Registry, Fondazione IRCCS Istituto Nazionale dei Tumori); Massimo Ruggie (Veneto Cancer Registry); Paolo Baili, Pamela Minicozzi, Milena Sant, Carmen Tereanu (Fondazione IRCCS, National Cancer Institute, Milan); Silvia Francisci, Andrea Tavilla, Daniela Pierannunzio, Silvia Rossi, Mariano Santaquilani, Arnold Knijn (Istituto Superiore di Sanità, Rome); Santa Pildava (Latvian Cancer Registry); Giedre Smailyte (Lithuanian Cancer Registry); Neville Calleja, Dominic Agius (Malta National Cancer Registry, Health Information and Research); Tom Børge Johannesen (Norwegian Cancer Registry); Jadwiga Rachtan (Cracow Cancer Registry); Stanisław Gózdź (Kielce Cancer Registry); Jerzy Błaszczak, Kamila Kępska (Lower Silesia (Wrocław)); Gonçalo Forjaz de Lacerda (Açores Cancer Registry); Maria José Bento (Northern Portugal Cancer Registry); Ana Miranda (Southern Portugal Cancer Registry); Chakameh Safaei Diba (Slovakian National Cancer Registry); Tina Žagar (Cancer Registry of Republic of Slovenia); Enrique Almar (Albacete. Castilla-La Mancha Cancer Registry); Nerea Larrañaga, Arantza Lopez de Munain (Basque Country Cancer Registry); Ana Torrella-Ramos (Castellón-Valencia (breast); Cancer Registry); José María Díaz García (Cuenca Cancer Registry); Rafael Marcos-Gragera (Girona Cancer Registry); María José Sánchez (Granada Cancer Registry, CIBERESP, IBS.Granada); Carmen Navarro, Diego Salmeron (Murcia Cancer Registry, CIBERESP, IMIB-Arrixaca); Conchi Moreno-Iribas (Navarra Cancer Registry, CIBERESP); Jaume Galceran, Marià Carulla (Tarragona Cancer Registry); Mohsen Mousavi (Basel Cancer Registry); Christine Bouchardy (Geneva Cancer Registry); Silvia M. Ess (Grisons-Glarus, St. Gallen Cancer Registry); Andrea Bordoni (Ticino Cancer Registry); Isabelle Konzelmann (Valais Cancer Registry); Jem Rashbass (Public Health England); Anna Gavin (Northern Ireland Cancer Registry); David H Brewster (Scotland Cancer Registry); Dyfed Wyn Huws

(Welsh Cancer Intelligence and Surveillance Unit); Vincent KY Ho (The Netherlands Cancer Registry); Ellen Benhamou (Institut de Cancérologie Gustave Roussy, Villejuif, France)

**Table S1. Annual number of cases observed and Estimated MAV indicator, by cancer, from the pool of the seven countries.**

Group of cancer	Cases	Estimated MAV							
		POOL	Belgium	Bulgaria	Finland	Ireland	Netherlands	Slovenia	Navarra
Haed & Neck	6749	82.6	45.8	86.5	32.5	66.8	94.2	218.4	38.1
Epithelial Ovary	3102	20.0	10.6	30.3	17.7	11.3	12.8	62.2	16.2
Oesophagus	2168	23.0	17.0	3.7	8.8	37.5	27.2	22.7	4.6
Central Nervous System	2144	35.4	21.0	29.0	8.7	61.4	35.9	57.7	12.1
Soft Tissue Sarcoma	1968	11.9	9.6	11.1	11.3	7.1	15.4	19.2	6.3
Thyroid	1669	21.3	14.3	16.7	18.1	9.3	11.6	75.3	13.6
Testis	1369	13.3	4.6	7.4	7.2	10.9	10.4	46.9	2.2
Biliary Tract	838	6.4	4.7	6.2	5.3	2.6	7.8	14.5	7.2
Urinary Tract	816	4.1	3.5	3.8	2.1	1.4	4.6	10.3	3.7
GEP	763	4.2	4.0	1.1	6.7	1.3	3.8	5.7	1.5
Vagina	701	7.5	3.0	9.3	5.9	3.9	11.4	11.0	2.5
Liver	566	7.1	9.7	6.6	5.5	3.5	7.0	5.4	2.3
Mesothelioma	530	5.3	5.2	2.5	3.2	1.2	5.8	12.3	2.3
Bone Sarcoma	387	10.8	5.5	4.1	5.3	3.8	21.9	5.4	1.0
Anal Canal	322	4.2	2.7	2.3	2.0	4.5	5.7	9.2	1.2
Penis	254	4.0	1.0	1.8	1.1	0.9	10.4	2.7	1.0
Melanoma of uvea	245	21.1	12.4	1.8	4.5	3.1	39.5	6.9	0.6
Small Intestine	200	1.2	1.2	1.0	1.3	0.5	1.5	1.2	1.0
Neuroendocrine carcinoma of skin	135	1.0	0.9	0.3		0.7	1.3	0.9	
Non epithelial Ovary	113	1.1	0.8	2.0	0.5	0.4	0.9	1.1	0.2
Endocrine carcinoma of thyroid	87	1.4	1.2	0.9	0.7	0.4	1.6	4.0	0.6
Thymus	74	1.0	0.7	0.8	0.4	0.8	1.4	1.3	0.6
Nephroblastoma	71	4.0	3.3	1.8	1.6	6.1	5.9	2.1	0.2
Melanoma of mucosa	65	0.9	0.4	0.4	0.8	0.6	1.4	1.0	0.2
Embryonal CNS	55	2.3	1.6	1.6	1.0	4.4		2.6	1.5
Adrenal cortex	54	0.9	0.7	1.6	0.4	0.3	1.1	1.2	0.2
Neuroblastoma	43	2.2	1.8	1.7	0.6	3.6	2.3	0.7	0.7
Retinoblastoma	41	7.7	4.9	0.4	1.3	2.2	14.8	0.7	0.2
Trachaea	33	0.8	0.4	1.0	0.4	0.4	0.8	2.1	0.3
Eye	21	0.7	0.3	0.7	0.1	0.3	1.1	0.9	0.4
Olfactory Neuroblastoma	17	0.5	0.5	0.7	0.4	0.2	0.7	0.3	
Placenta	14	0.4	0.3	0.4	0.2	0.1	0.5	0.1	0.2
Hepatoblastoma	10	1.0	0.6	0.5	0.3	1.5	1.2	0.4	
Middle ear	10	0.4	0.4	0.6	0.2	0.3	0.5	0.1	
Parathyroid	9	0.3	0.3	0.5	0.3	0.2	0.5	0.1	0.2
Pituitary	3	0.2	0.3		0.3	0.2	0.3		
Parcreatoblastoma	1	0.3		0.3					
Pleuropulmonary blastoma	0	0.2			0.1		0.3		

**Table S2. Annual incidence rate for sex specific rare cancers**

Family	Cancer entity	Crude Incidence Rate per 100,000 per year	95% Confidence Interval	
			lower	upper
<b>Female genital rare cancers</b>		<b>44.39</b>	44.25	44.55
	<b>RARE EPITHELIAL TUMOURS OF BREAST</b>	8.05	7.99	8.12
	Mammary Paget's disease of breast	0.81	0.79	0.83
	Special types of adenocarcinoma of breast	5.99	5.93	6.04
	Metaplastic carcinoma of breast	0.20	0.19	0.21
	Salivary gland type tumours of breast	0.11	0.10	0.12
	Epithelial tumour of male breast	1.02	1.00	1.04
	<b>RARE EPITHELIAL TUMOURS OF CORPUS UTERI</b>	1.38	1.35	1.40
	Squamous cell carcinoma with variants of corpus uteri	0.13	0.12	0.13
	Adenoid cystic carcinoma of corpus uteri	0.00	0.00	0.00
	Clear cell adenocarcinoma, NOS of corpus uteri	0.32	0.30	0.33
	Serous (papillary) carcinoma of corpus uteri	0.15	0.14	0.16
	Mullerian mixed tumour of corpus uteri	0.78	0.76	0.80
	<b>EPITHELIAL TUMOURS OF CERVIX UTERI</b>	12.26	12.18	12.33
	Squamous cell carcinoma with variants of cervix uteri	9.24	9.17	9.30
	Adenocarcinoma with variants of cervix uteri	1.78	1.75	1.81
	Undifferentiated carcinoma of cervix uteri	0.06	0.05	0.07
	Mullerian mixed tumour of cervix uteri	0.03	0.03	0.04
	<b>EPITHELIAL TUMOUR OF OVARY AND FALLOPIAN TUBE</b>	18.31	18.22	18.41
	Adenocarcinoma with variants of ovary	11.63	11.55	11.70
	Mucinous adenocarcinoma of ovary	1.50	1.48	1.53
	Clear cell adenocarcinoma of ovary	0.59	0.58	0.61
	Primary peritoneal serous/papillary carcinoma of ovary	0.16	0.15	0.17
	Mullerian mixed tumour of ovary	0.28	0.27	0.29
	Adenocarcinoma with variant of fallopian tube	0.33	0.32	0.35
	<b>NON EPITHELIAL TUMOURS OF OVARY</b>	0.50	0.48	0.51
	Sex cord tumours of ovary	0.25	0.24	0.26
	Malignant/Immature teratomas of ovary	0.10	0.10	0.11
	Germ cell tumour of ovary	0.14	0.13	0.15
	<b>EPITHELIAL TUMOURS OF VULVA AND VAGINA</b>	3.86	3.81	3.90
	Squamous cell carcinoma with variants of vulva and vagina	3.29	3.25	3.33
	Adenocarcinoma with variants of vulva and vagina	0.14	0.13	0.15
	Paget's disease of vulva and vagina	0.09	0.09	0.10
	Undifferentiated carcinoma of vulva and vagina	0.01	0.01	0.01
	<b>TROPHOBLASTIC TUMOUR OF PLACENTA</b>	0.05	0.04	0.05
	Choriocarcinoma of placenta	0.04	0.04	0.05
<b>Male genital and urogenital rare cancers</b>		<b>14.53</b>	14.45	14.63
	<b>RARE EPITHELIAL TUMOURS OF PROSTATE</b>	1.23	1.21	1.26
	Squamous cell carcinoma with variants of prostate	0.04	0.03	0.04
	Infiltrating duct carcinoma of prostate	1.05	1.03	1.08
	Transitional cell carcinoma of prostate	0.13	0.12	0.13
	Salivary gland type tumours of prostate	0.02	0.01	0.02
	<b>TESTICULAR AND PARATESTICULAR CANCERS</b>	6.75	6.69	6.81
	Paratesticular adenocarcinoma with variants	0.00	0.00	0.00
	Non seminomatous testicular cancer	2.59	2.56	2.63
	Seminomatous testicular cancer	3.73	3.69	3.77
	Spermatocytic seminoma	0.07	0.06	0.07
	Teratoma with malignant transformation	0.00	0.00	0.00